Amgen, Novartis biosimilars news

Novartis’ Sandoz Inc. generics unit filed a motion in the U.S. District Court for the Northern District of California seeking an order to dismiss patent infringement and related claims from Amgen related to Sandoz’s application to market Zarxio, a biosimilar

Read the full 402 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE